GNAT2

Across TCGA pan-cancer cohorts, GNAT2 RNA is linked to patient survival in 8 of 34 cancer types, making it the most broadly survival-associated GNAT2 data layer compared with 3 for mutation status.

The strongest signal is observed in uterine carcinosarcoma (UCS), where higher GNAT2 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated GNAT2 expression acts as an unfavorable survival marker, although some lineages such as COAD show a favorable association.

UCS, STAD, and THCA are the cancer types where GNAT2 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCS	DFS	Tertile	III,IV	0.108	0.442	.011	72	view →
STAD	OS	Tertile	All	0.104	0.538	.011	45	view →
THCA	OS	Tertile	IV	0.790	1.000	.016	18	view →
PAAD	OS	Tertile	All	0.261	0.509	.020	18	view →
ESCA	OS	Tertile	All	0.211	0.876	.028	18	view →
DLBC	OS	Tertile	II,III,IV	0.118	0.802	.025	18	view →
SCLC	DFS	Tertile	IV	0.201	0.776	.024	9	view →
COAD	DFS	Tertile	II,III,IV	0.752	0.417	.043	3	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

GNAT2–UCS (DFS)

Open the UCS breakdown →